FROM WASHINGTON EXAMINER: Advocates of the Make America Healthy Again agenda have expressed skepticism over President Donald Trump’s agreement with pharmaceutical companies to lower prices and expand access to blockbuster anti-obesity and diabetes medications.
Following Trump’s Oval Office announcement Thursday about drastically lowering costs for Ozempic and other GLP-1 drugs, MAHA leaders told the Washington Examiner that they would prefer to see an elevation of holistic medicine and improved nutrition quality, rather than pharmaceuticals, as the way to end the obesity epidemic in the United States.
Trump and Health and Human Services Secretary Robert F. Kennedy Jr. announced that the administration had struck a deal with pharmaceutical giants Novo Nordisk and Eli Lilly, pioneers in the GLP-1 drug class targeting obesity and Type 2 diabetes.
Jennifer Galardi, policy expert for the Restoring American Wellness initiative at the Heritage Foundation, expressed skepticism. Galardi Told the Washington Examiner GLP-1 drugs being more accessible and cheaper is “philosophically incoherent” with MAHA’s core tenet of holistic and diet-based medicine.
“In my eyes, it works against the message of the MAHA movement, which encourages root cause treatment to curb chronic disease spending,” said Galardi.
Read more at the Washington Examiner.
